Palo Santo Fund
Early-stage venture firm focused on neuroscience and psychedelic-related companies. Provides capital, portfolio support, and access to scientific, clinical and industry networks to advance therapeutics, discovery platforms, and delivery models for mental health.
Industries
Nr. of Employees
small (1-50)
Palo Santo Fund
Services
Providing funding to companies developing neuroscience therapeutics, discovery platforms, and supporting technologies.
Advisory, go-to-market planning, partnership introductions, and transaction support for portfolio companies.
Publishing curated news, research highlights, and media coverage related to psychedelic science and mental health innovation.
Providing funding to companies developing neuroscience therapeutics, discovery platforms, and supporting technologies.
Advisory, go-to-market planning, partnership introductions, and transaction support for portfolio companies.
Publishing curated news, research highlights, and media coverage related to psychedelic science and mental health innovation.
Expertise Areas
- Venture investing in neuroscience and psychedelic-enabled therapeutics
- Clinical development support for CNS and psychedelic therapies
- Regulatory strategy for expedited review pathways
- Scientific advisory convening and academic collaboration
Key Technologies
- Psychedelic-assisted therapy modalities
- Machine-learning-driven drug discovery
- Patient-derived neural models
- Neuroplasticity-targeting pharmacology
News & Updates
Coverage summarizing a study that investigated ketamine combined with an alcohol-cue exercise to reduce harmful drinking; includes discussion of study design, limitations (sample size, follow-up), and interpretation by external experts.
Reported 21 core investments in next-generation neuroscience therapeutics.
Reported partnerships with pharmaceutical and biotechnology companies (site cites multiple strategic collaborations).
Reported six Breakthrough Therapy designations connected to portfolio programs.
Reported portfolio involvement in over 350 clinical trials worldwide.
Reported engagement across 21 academic institutions.
Coverage summarizing a study that investigated ketamine combined with an alcohol-cue exercise to reduce harmful drinking; includes discussion of study design, limitations (sample size, follow-up), and interpretation by external experts.
Reported 21 core investments in next-generation neuroscience therapeutics.
Reported partnerships with pharmaceutical and biotechnology companies (site cites multiple strategic collaborations).
Reported six Breakthrough Therapy designations connected to portfolio programs.
Reported portfolio involvement in over 350 clinical trials worldwide.
Reported engagement across 21 academic institutions.